140 related articles for article (PubMed ID: 1026330)
1. Computer simulation of leukemia therapy: combined pharmacokinetics, intracellular enzyme kinetics, and cell kinetics of the treatment of L1210 leukemia by cytosine arabinoside.
Lincoln T; Morrison P; Aroesty J; Carter G
Cancer Treat Rep; 1976 Dec; 60(12):1723-39. PubMed ID: 1026330
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
Avramis VI; Powell W
Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
[TBL] [Abstract][Full Text] [Related]
3. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
Li ZR; Campbell J; Rustum YM
Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
[TBL] [Abstract][Full Text] [Related]
4. Combined effect of cytosine arabinoside and thiopurines.
Valeriote F; Vietti T; Edelstein M
Cancer Treat Rep; 1976 Dec; 60(12):1925-34. PubMed ID: 1026347
[TBL] [Abstract][Full Text] [Related]
5. Use of cell-cycle information in the preparation of drug combinations: results with cytosine arabinoside plus actinomycin D1,2.
Bhuyan BK; Fraser TJ; Day KJ
Cancer Treat Rep; 1976 Dec; 60(12):1813-8. PubMed ID: 1036090
[TBL] [Abstract][Full Text] [Related]
6. Characterization of tumor cell heterogeneity of a murine leukemia cell line (L1210) in response to arabinosylcytosine: quantitation using a computerized image analysis system.
Raymakers RA; Slocum HK; Minderman H; Malmberg M; Rustum YM
Exp Hematol; 1993 May; 21(5):602-7. PubMed ID: 8513859
[TBL] [Abstract][Full Text] [Related]
7. Correlation of mouse tissue distribution of arabinosylcytosine in vivo with enzymatic activities in vitro.
Ho DH
Drug Metab Dispos; 1976; 4(3):296-300. PubMed ID: 6236
[TBL] [Abstract][Full Text] [Related]
8. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
Riva CM; Rustum YM
Cancer Res; 1985 Dec; 45(12 Pt 1):6244-9. PubMed ID: 2998596
[TBL] [Abstract][Full Text] [Related]
9. [Experimental study on the correlation between the antitumor activity and pharmacokinetics of cytosine arabinoside (Ara-C) and N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC)].
Takenaka T; Kimura K
Nihon Gan Chiryo Gakkai Shi; 1985 Dec; 20(10):2322-8. PubMed ID: 3831176
[No Abstract] [Full Text] [Related]
10. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
[TBL] [Abstract][Full Text] [Related]
11. Paradoxical effect of cytosine arabinoside on mouse leukemia cell line L1210 cells.
Nakayama T; Sakamoto S; Sassa S; Suzuki S; Kudo H; Nagasawa H
Anticancer Res; 2005; 25(1A):157-60. PubMed ID: 15816533
[TBL] [Abstract][Full Text] [Related]
12. Disposition of cytosine arabinoside (NSC-63878) and its metabolites: a pharmacokinetic simulation.
Morrison PF; Lincoln TL; Aroesty J
Cancer Chemother Rep; 1975; 59(4):861-76. PubMed ID: 169990
[TBL] [Abstract][Full Text] [Related]
13. Increased activation of 1-beta-D-arabinofuranosylcytosine by hydroxyurea in L1210 cells.
Walsh CT; Craig RW; Agarwal RP
Cancer Res; 1980 Sep; 40(9):3286-92. PubMed ID: 7427943
[TBL] [Abstract][Full Text] [Related]
14. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine.
Capizzi RL; White JC; Powell BL; Perrino F
Semin Hematol; 1991 Jul; 28(3 Suppl 4):54-69. PubMed ID: 1780754
[TBL] [Abstract][Full Text] [Related]
15. Phospholipid derivatives of nucleoside analogs as prodrugs with enhanced catabolic stability.
Matsushita T; Ryu EK; Hong CI; MacCoss M
Cancer Res; 1981 Jul; 41(7):2707-13. PubMed ID: 7248939
[TBL] [Abstract][Full Text] [Related]
16. Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase.
Brockman RW; Cheng YC; Schabel FM; Montgomery JA
Cancer Res; 1980 Oct; 40(10):3610-5. PubMed ID: 6254636
[TBL] [Abstract][Full Text] [Related]
17. [Chemotherapy of the malignancies from the viewpoint of pharmacology and biochemistry of cytosine arabinoside (ara-C) and its derivatives].
Nakamura T; Ueda T
Gan To Kagaku Ryoho; 1982 Aug; 9(8):1339-51. PubMed ID: 6191711
[TBL] [Abstract][Full Text] [Related]
18. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
Schwartz SA; Morgenstern B; Capizzi RL
Cancer Res; 1982 Jun; 42(6):2191-7. PubMed ID: 7074600
[TBL] [Abstract][Full Text] [Related]
19. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia.
Boos J; Hohenlöchter B; Schulze-Westhoff P; Schiller M; Zimmermann M; Creutzig U; Ritter J; Jurgens H
Med Pediatr Oncol; 1996 Jun; 26(6):397-404. PubMed ID: 8614376
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response.
Burke PJ; Karp JE; Vaughan WP
J Natl Cancer Inst; 1981 Sep; 67(3):529-38. PubMed ID: 6944525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
